Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAetna Part B preferred drug list Coverage | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy N/A

    Preferred drug list for Aetna Medicare Advantage with drug coverage plans (PDF)

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Aetna Medicare Advantage plans that offer Part B drug coverage: lists drug categories, preferred and non-preferred medically administered (Part B) drugs, associated HCPCS/J-codes, and notes on step therapy, medical necessity, and prior authorization requirements. This is part 1 of 3 and contains multiple categories and drugs with their codes and brief coverage/PA notes or links to criteria.

    Policy Summary
    PayerAetna
    PolicyPreferred drug list for Aetna Medicare Advantage with drug coverage plans (PDF)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionProviders must use preferred products listed in a class before a non-preferred product will be covered when step therapy applies; see linked step therapy criteria for details and for specific indications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical/coverage changes — has_material_change = false

    30+Drug products listed in part 1
    multipleCategories covered (examples)
    manyPA not required noted
    Multiple
    Categories with step therapy
    ~100+Products/Codes in Part 2

    Coverage Summary

    Complement inhibitors (examples: treatments for paroxysmal nocturnal hemoglobinuria [PNH], atypical hemolytic uremic syndrome [aHUS], and other complement‑mediated disorders) are included in this Part B list and may have specific prior authorization and exception requirements. For these agents, the policy requires documentation of diagnosis, relevant laboratory and clinical response data, and prior use or intolerance of preferred agents when step therapy is applicable. For specific coverage details and required supporting documentation, use the medical necessity and step therapy criteria links in each drug entry and submit via the indicated fax form.

    Prior authorization exceptions: An exception to step therapy or preferred‑product requirements may be granted when the prescriber documents that the preferred product is contraindicated, not tolerated, or expected to be clinically ineffective for the individual patient. The exception request must reference the patient diagnosis, relevant prior therapies and outcomes, and any supporting clinical rationale. Exception requests are processed per the medical necessity criteria for the specific drug / indication; use the fax request form linked on the drug entry. When PA is not required for a given HCPCS code, that is noted in the drug entry.

    General step therapy / preferred drug logic

    General step therapy and preferred‑product logic applied across the document:

    ALL of the following

    • A preferred product must be tried first when step therapy is listed for the indication (preferred‑product‑first).
    • Documentation must show an adequate trial of the preferred product (duration and dosing per the linked step therapy criteria) unless a documented contraindication or intolerance exists.
    • If the preferred product is ineffective or not tolerated, the prescriber may request coverage of a non‑preferred product by submitting clinical documentation per the linked medical necessity criteria and the fax request form.
    • Some categories require sequential trials across tiers (e.g., both tier‑1 and tier‑2 preferred products) before non‑preferred products will be considered; these tier rules are called out in the specific category entries.
    • When PA is explicitly not required for a specific HCPCS code, that will be indicated in the drug entry; however, other administrative documentation (e.g., chart notes) may still be necessary for clinical review.

    General coverage model reflected in document

    General coverage and administrative routing model used for every drug or category entry in this Part B list:

    ALL of the following

    • HCPCS code(s): Each entry lists the billing HCPCS code(s) (or misc codes such as J3590/C9399 when applicable).
    • Medical necessity criteria link: The specific clinical criteria that must be met for approval are linked from the entry; these define diagnosis, prior therapy, laboratory, and monitoring requirements.
    • Step therapy: If step therapy applies for the listed indication, the entry states this and links to the step therapy decision logic; includes required trial duration/dosing thresholds as defined in the step therapy criteria.
    • Prior authorization (PA) notes: Entries will indicate whether PA is required or not required for the HCPCS code; when PA is required, instructions and fax form links are provided.

    Initial Therapy Criteria (step therapy / preferred product tiers)

    Alpha-1 proteinase inhibitors

    Alpha-1 antitrypsin deficiency is subject to step therapy; preferred products must be used before non-preferred products.

    Alpha-1 step therapy: Indication: Alpha-1 antitrypsin deficiency - Preferred drugs: Prolastin-C, Zemaira; Non-preferred examples: Aralast NP, Glassia (HCPCS J0256)

    Document lists preferred and non-preferred alpha-1 products and specifically notes Glassia J0256

    Bone resorption inhibitors (osteoporosis and other indications)

    Osteoporosis indications are subject to the bone-resorption step therapy structure: first-tier preferred agents (e.g., Zoledronic acid) may be required prior to moving to second-tier preferred or non-preferred products. Many entries include HCPCS codes and links to medical necessity/step therapy criteria and fax forms.

    Osteoporosis initial preferred therapy: Indication: Osteoporosis - Zoledronic acid (HCPCS J3489) is listed with 'Prior authorization is not required' and 'Step therapy: None' as a first-line preferred product

    Zoledronic acid entry shows HCPCS J3489 and PA not required

    Continuation Therapy Criteria

    General step therapy / preferred drug logic

    Many categories and indications in this list are subject to step therapy; continuation/ongoing-treatment rules require documentation of trials/failures per linked criteria and specify where to find those links.

    Continuation/ongoing-treatment - general: Where indicated, coverage is conditional upon step therapy for specific indications as listed; providers must document trials/failures per the linked step therapy/medical necessity criteria

    Document repeatedly instructs providers to follow linked criteria and to document trials/failures

    Examples of categories with step therapy noted: Examples: Gonadotropin-releasing hormone agonists (advanced prostate cancer, gender dysphoria, recurrent AR+ salivary gland tumors), Intravenous iron (after intolerance or unsatisfactory response to oral iron), VEGF inhibitors (ophthalmic) require preferred product trials before non-preferred products, PD-1/PD-L1 agents have specific indications subject to step therapy per linked criteria

    These categories and indications are specifically identified in the document as subject to step therapy

    Where to find linked criteria:

    Exceptions / Exclusions / Routing

    Some subcutaneous (SC) products and other entries are routed to Medicare Part D rather than Part B; for example, Hadlima, Rinvoq, Skyrizi SC, Stelara SC, Pyzchiva SC, Yesintek SC, Tremfya SC and other SC agents list 'HCPCS code = Not applicable' and instruct 'See Part D benefit' or 'Request through Part D'. Several entries explicitly say 'Request through Part D' or 'See Part D benefit' (providers should submit requests through Part D processes when indicated).

    Applicable Codes

    HCPCS / J-codes explicitly listed (examples)mixed
    J0256Glassia (alpha-1 proteinase inhibitor) - listed as non-preferred
    J0257Listed in alpha-1 section (appearance in document)
    J3489Zoledronic acid
    Q5136Jubbonti / multiple product category code used repeatedly (category Q-code)
    J0897Prolia / Xgeva (denosumab) - appears for multiple denosumab products
    J3111Evenity
    Q5158Conexxence / Bomyntra / denosumab-bnht - Q-code
    Q5159Ospomyv / Xbryk - Q-code
    Q5157Stoboclo / Osenvelt - Q-code
    Q5162Bildyos / Bilprevda - Q-code
    1–10 of 50
    1/5
    Gonadotropin-releasing hormone agonistsHCPCS
    J9217Lupron depot / Eligard mapping (Eligard also referenced as J0881 = J9217 in doc)
    J3315Trelstar
    J9202Zoladex
    J0881Preferred drugs, mapped in doc (Eligard referenced)
    Gonadotropin-releasing hormone antagonistsHCPCS
    J9155Firmagon
    Immunologics (IV biologics)HCPCS
    Q5103Inflectra
    Q5104Renflexis
    Q5121Avsola
    J1745Remicade
    J3380Entyvio IV
    J1628Tremfya IV
    Q9997Pyzchiva IV
    Intravenous iron productsHCPCS
    J1750Infed (iron dextran)
    J1756Venofer
    Q0139Feraheme
    Q0138Feraheme (additional code)
    J1439Injectafer
    J1437Monoferric
    IVIG productsHCPCS
    J1561Gammaked / Gamunex-C
    J1459Privigen
    J1552Alyglo
    J1554Asceniv
    J1556Bivigam
    J1572Flebogamma
    J1569Gammagard Liquid
    J1553Yimmugo
    SCIG productsHCPCS
    J1561Gammaked / Gamunex-C (SCIG mapping referenced)
    J1559Hizentra
    J1558Xembify
    J1551Cutaquig
    J1555Cuvitru
    J1575HyQvia
    J1569Gammagard Liquid
    Multiple sclerosis therapiesHCPCS
    J2350Ocrevus
    J2351Ocrevus Zunovo
    J2329Briumvi
    J0202Lemtrada
    J2323Tysabri
    Breast cancer / HER2-targeted agentsHCPCS
    J9316Phesgo
    J9306Perjeta
    Q5117Kanjinti
    Q5112Ontruzant
    Q5113Herzuma
    Q5114Ogivri
    Q5116Trazimera
    J9355Herceptin
    J9356Herceptin Hylecta
    Q5146Hercessi
    Rituxan and biosimilarsHCPCS
    Q5119Ruxience
    Q5115Truxima
    Q5123Riabni
    J9312Rituxan
    J9311Rituxan Hycela
    Liposarcoma agentsHCPCS
    J9179Halaven
    J9352Yondelis
    Multiple myeloma agentsHCPCS
    J9046Bortezomib/Velcade (J9046/J9048/J9049 referenced)
    J9054Boruzu
    J9145Darzalex
    J9144Darzalex Faspro
    J9176Empliciti
    J9047Kyprolis
    J9227Sarclisa
    PD-1 / PD-L1 inhibitors (oncology)HCPCS
    J9119Placeholder non-specific PD1/PDL1 group mapping in doc
    J9271Keytruda
    J9277Keytruda Qlex
    J9173Imfinzi
    J9299Opdivo
    J9289Opdivo Qvantig
    J9022Tecentriq
    J9024Tecentriq Hybreza
    J9119Libtayo mapping (doc uses J9119 for Libtayo as well)
    Pemetrexed / AlimtaHCPCS
    J9305Alimta
    J9294Pemetrexed (one of multiple codes)
    J9296Pemetrexed
    J9297Pemetrexed
    J9314Pemetrexed
    Osteoarthritis injections / corticosteroidsHCPCS
    J1010Methylprednisolone acetate
    J3300Triamcinolone acetonide
    J3301Triamcinolone acetonide (other mapping)
    J3304Zilretta
    Somatostatin analoguesHCPCS
    J1930Somatuline depot
    J2353Octreotide acetate depot
    J2502Sandostatin LAR
    VEGF inhibitors (ophthalmic) - 1st tier preferredHCPCSCovered
    C9257Bevacizumab (Avastin) - ophthalmic mapping / misc
    J7999Bevacizumab (Avastin) - misc billing code
    Q5124Byooviz
    J0178Eylea
    J0177Eylea HD
    Q5147Pavblu
    J3590Eydenzelt misc code mapping
    C9399Eydenzelt misc code mapping
    VEGF inhibitors (ophthalmic) - other productsHCPCS
    Q5149Enzeevu
    Q5150Ahzantive
    Q5153Opuviz
    Q5155Yesafili
    J0179Beovu
    Q5128Cimerli
    J2778Lucentis
    J2779Susvimo
    J2777Vabysmo
    Paclitaxel (protein-bound) / AbraxaneHCPCS
    J9264Abraxane / paclitaxel (protein-bound)
    Ophthalmology - intravitreal and related agentsHCPCS
    Q5124Byooviz
    J0178Eylea
    J0177Eylea HD
    Q5147Pavblu
    Q5149Enzeevu
    J2778Lucentis
    J2779Susvimo
    J2777Vabysmo
    J0179Beovu
    Q5128Cimerli
    1–10 of 14
    1/2
    Viscosupplements (single-injection)HCPCS
    J7318Durolane
    J7325Synvisc-one
    J7326Gel-one
    J7327Monovisc
    J7322Hymovis One
    J7323Euflexxa
    J7328Gelsyn-3
    J7320GenVisc
    J7321Hyalgan / Supartz FX / Visco-3
    J7324Orthovisc
    1–10 of 13
    1/2
    Viscosupplements (multiple-injection)HCPCS
    J7323Euflexxa
    J7325Synvisc
    J7321Supartz FX / Visco-3 / Hyalgan
    J7322Hymovis
    J7324Orthovisc
    Infliximab and biosimilars; related IV biologicsHCPCS
    Q5121Avsola
    Q5103Inflectra
    Q5104Renflexis
    J1745Remicade / Unbranded infliximab / multiple unbranded products
    Q5098Unbranded infliximab / Imuldosa IV mapping
    Q9999Otulfi IV mapping
    Q9998Selarsdi IV mapping
    J3590Starjemza IV
    Q5099Steqeyma IV
    Q5138Wezlana IV
    Other IV/biologic agentsHCPCS
    J0717Tyruko / Cimzia mapping
    J2323Tysabri
    J3262Actemra
    Q5156Avtozma
    Q5133Tofidence
    Q5119Ruxience
    Q5115Truxima
    Q5123Riabni
    J9312Rituxan
    J1602Simponi Aria
    1–10 of 13
    1/2
    PCSK9 inhibitorsHCPCS
    J1306Leqvio
    Anti-CGRP and migraine therapiesHCPCS
    J3032Vyepti
    Severe asthma and eosinophilic biologicsHCPCS
    J2786Cinqair
    J2182Nucala
    J2356Tezspire

    Provider Actions

    Step Therapy

    Step therapy required for listed indications

    Step therapy is required for certain indications listed in this policy. Providers must first use the listed preferred products for the specified medical indications (for example, preferred alpha‑1 proteinase inhibitors for alpha‑1 antitrypsin deficiency and specified preferred bone resorption inhibitors for osteoporosis and other listed indications). If the preferred product is ineffective or not tolerated, a non‑preferred product may be considered per the exception process. Follow the linked step therapy criteria for the specific indication when requesting coverage for non‑preferred products.

    • Use preferred products first for indications that list step therapy (see individual drug entries and linked step therapy criteria).
    • Exceptions are available when clinically appropriate; follow the exception process in the criteria links.
    Prior Authorization

    Prior authorization not required for many listed products

    Prior authorization is not required for many listed Part B drugs. Providers may bill directly without requesting prior authorization for these products.

    Background

    This preferred drug list (Part 1 of 3) identifies Aetna MAPD Part B preferred and non-preferred medically administered drugs, shows HCPCS/J/Q codes, and indicates when step therapy or prior authorization applies. Where listed, entries link to separate medical necessity and step therapy criteria and to fax request forms — providers must follow those linked criteria/forms when seeking coverage or exceptions.

    Preferred product: A drug the plan prefers and typically requires to be tried first under step therapy before covering non-preferred alternatives (see general step therapy guidance).

    Prior authorization is not required: The plan note indicating that a separate prior authorization is not needed for that product under the stated conditions (examples appear throughout the list).

    HCPCS: Healthcare Common Procedure Coding System codes used for billing medical benefit drugs and services.

    J/Q codes: J-codes and Q-codes used to bill specific injectable drugs and biologics under the medical benefit.

    Part D benefit: Prescription drug benefit administered under Medicare Part D; items routed through Part D are not covered under the Part B medical benefit in this list.

    HCPCS/J-code: Code used for billing certain injectable/infused drugs under the medical benefit.

    Clinical Evidence

    This document does not contain discrete trial metrics or clinical evidence tables within Part 1. For clinical justification, step therapy and coverage decisions the policy directs providers to the externally linked medical necessity and step therapy criteria (see the product-level notes that say 'Link to criteria', 'See step therapy criteria', or provide a link to a criteria PDF) and to the specified fax request forms.

    Revision History

    Policy Summary
    PayerAetna
    PolicyPreferred drug list for Aetna Medicare Advantage with drug coverage plans (PDF)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionProviders must use preferred products listed in a class before a non-preferred product will be covered when step therapy applies; see linked step therapy criteria for details and for specific indications.
    SourceLink
    On This Page
    Coverage SummaryInitial Therapy Criteria (step therapy / preferred product tiers)Continuation Therapy CriteriaExceptions / Exclusions / RoutingApplicable CodesProvider ActionsBackgroundClinical EvidenceRevision History
    Fax request form: Each entry provides the fax request form or link used to submit clinical documentation for initial or continuation requests and for exception requests.
  1. Tiering and sequencing: When products are tiered, the entry identifies preferred first‑line products, second‑tier preferred alternatives (and required sequencing), and non‑preferred products that require prior trial/failure of preferred options.
  2. Exception process: The pathway to request an exception to step therapy or preferred‑product requirements is specified (refer to medical necessity criteria and fax form); required documentation for exceptions is described in the criteria link.
  3. Complement inhibitors and other specialty categories: For high‑complexity classes (e.g., complement inhibitors for PNH or aHUS), entries explicitly call out diagnosis‑specific requirements, required laboratory parameters, and ongoing monitoring documentation needed for continuation approvals.
  4. Second-tier preferred and other agents: 2nd tier preferred drugs after trial/failure of Zoledronic acid include: Jubbonti (Q5136), Prolia (J0897), Evenity (J3111), Conexxence/denosumab-bnht (Q5158) and numerous other denosumab/Q-code products — each entry links to medical necessity, step therapy criteria, and a fax request form

    Document lists multiple HCPCS/Q-codes with links to criteria and fax forms

    Bone resorption inhibitors (hypercalcemia of malignancy and other indications)

    For hypercalcemia of malignancy and prevention of skeletal events, initial therapy with pamidronate or zoledronic acid is expected; second-tier preferred denosumab-type agents and other products require prior trial/failure of first-line agents and link to criteria/forms.

    Initial agents: Indications: hypercalcemia of malignancy and prevention of skeletal events — Pamidronate (HCPCS J2430) and Zoledronic acid (HCPCS J3489) are listed as first-line agents with 'Prior authorization is not required' and 'Step therapy: None'

    Pamidronate and Zoledronic acid entries indicate no PA and no step therapy

    Second-tier after trial/failure: After trial/failure of Pamidronate or Zoledronic acid, 2nd tier preferred drugs include Xgeva (J0897) and multiple Q/J-coded denosumab or related products (Wyost Q5136; Bomyntra/Denosumab-bnht Q5158; Osenvelt Q5157; Xbryk Q5159; Aukelso Q5161; Bilprevda Q5162; others) — entries link to medical necessity/step therapy criteria and fax forms

    Document enumerates these second-tier products and references links to criteria/forms

    Botulinum toxins

    Botulinum toxin indications such as blepharospasm and cervical dystonia are subject to step therapy; certain products are preferred and do not require prior authorization while others are non-preferred and link to criteria/forms.

    Preferred botulinum products: Preferred drugs: Botox (HCPCS J0585) and Xeomin (HCPCS J0588) — both entries indicate 'Prior authorization is not required'

    Document marks Botox and Xeomin as preferred and PA not required

    Non-preferred botulinum products: Non-preferred: Daxxify (J0589), Dysport (J0586; links to criteria and fax form), Myobloc (J0587)

    Non-preferred botulinum products are listed; Dysport specifically links to criteria and fax form

    VEGF inhibitors (ophthalmic) - intravitreal/related agents

    Ophthalmic VEGF inhibitors are organized in tiers; a preferred product from each tier (including bevacizumab mappings and biosimilars/approved ophthalmic agents) is expected before covering non-preferred ophthalmic VEGF agents. Entries list HCPCS/Q/J codes and link to medical necessity/step therapy criteria and fax forms.

    Tiered ophthalmic VEGF step therapy: Category: VEGF inhibitors (ophthalmic) — 'Preferred product from both tiers required prior to receiving a non-preferred product'

    Category header explicitly states tiered preferred product requirement

    First-tier preferred examples: First-tier preferred includes bevacizumab (Avastin) ophthalmic mappings (C9257 / J7999) with 'Prior authorization is not required' and approved biosimilars/agents such as Byooviz (Q5124), Eylea (J0178/J0177), Pavblu (Q5147) — entries include HCPCS and links where applicable

    Document lists 1st tier preferred agents with codes and PA notes

    Other ophthalmic agents requiring prior trial: Other products listed (Ahzantive Q5150, Enzeevu Q5149, Opuviz Q5153, Yesafili Q5155, Beovu J0179, Cimerli Q5128, Lucentis J2778, Susvimo J2779, Vabysmo J2777, Eydenzelt misc codes) are in other tiers or non-preferred and link to criteria/fax forms; coverage follows the tiered requirement

    Multiple non-preferred ophthalmic agents are enumerated with codes and links

    Each category/drug entry that is subject to step therapy or prior authorization includes links to 'Medical necessity criteria', 'Step therapy criteria', and 'Fax request form' which must be followed for coverage and continuation

    Numerous entries show 'Link to criteria' and 'Link to fax form' fields

    • Examples of HCPCS/J/Q codes that do NOT require prior authorization: J3489, J2430, J2506, Q5101, J0885, J1786, J3385, J0585, J7211, J2782, J2781
    • Pamidronate (J2430) and zoledronic acid (J3489) are explicitly noted as prior authorization not required for their listed indications.
    Documentation Required

    Follow linked medical necessity and fax request forms

    Follow the Aetna medical necessity and step therapy criteria and use the specified fax request forms when requesting authorization or submitting clinical documentation. Linked criteria and fax forms provide the requirements that must be met for approval.

    • Use the medical necessity and step therapy criteria links for specific drugs (e.g., bone resorption inhibitors, botulinum toxins, alpha‑1 proteinase inhibitors).
    • Use the linked fax request forms when a form is indicated for submitting documentation for authorization.
    Billing Rule

    Billing rules — use specified HCPCS/Q/J codes when billing

    When billing, use the correct HCPCS/Q/J codes listed for each product. Correct coding ensures claims are routed appropriately between Medicare Part B and Part D and supports accurate processing of coverage determinations.

    • Bill with the HCPCS/Q/J codes shown in the policy for each product (examples: J3489, J2430, J0256, J0257, J0897, Q5136, J0585, J0588, J0586, J0587, J0589, J3111, Q5158, Q5159, Q5157, Q5161, Q5162, J3590/C9399 for miscellaneous).
    • Using the specified HCPCS/J/Q codes directs claims to Part B vs Part D as appropriate.
    Documentation Required

    Route certain SC products via Part D when indicated

    Certain subcutaneous (SC) agents may be routed through Part D processes even though they are included in this document. When the policy or codes indicate Part D routing for specific SC products, follow Part D billing and coverage processes accordingly.

    • If an SC product is designated to route via Part D in the policy or by coding, submit claims and prior authorization requests through Part D processes per payer instructions.
    • Confirm routing when using miscellaneous codes (e.g., J3590/C9399) or product‑specific guidance that indicates Part D handling.